WO2021231314A8 - Methods of treating covid-19 using tetracycline compounds - Google Patents

Methods of treating covid-19 using tetracycline compounds Download PDF

Info

Publication number
WO2021231314A8
WO2021231314A8 PCT/US2021/031608 US2021031608W WO2021231314A8 WO 2021231314 A8 WO2021231314 A8 WO 2021231314A8 US 2021031608 W US2021031608 W US 2021031608W WO 2021231314 A8 WO2021231314 A8 WO 2021231314A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
infection
treating
tetracycline compounds
viral
Prior art date
Application number
PCT/US2021/031608
Other languages
French (fr)
Other versions
WO2021231314A1 (en
Inventor
Gail OZER BERMAN
Alisa WALTERS SERIO
Amy L. Manley
Original Assignee
Paratek Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals, Inc. filed Critical Paratek Pharmaceuticals, Inc.
Publication of WO2021231314A1 publication Critical patent/WO2021231314A1/en
Publication of WO2021231314A8 publication Critical patent/WO2021231314A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present disclosure provides methods of treating or preventing a viral infection, e.g., SARS-CoV-2 infection or an influenza infection; for treating a viral disease, e.g., COVID-19 or influenza; for preventing a secondary bacterial pneumonia in a subject with a viral infection or a viral disease; and for modulating an immune response. The methods comprise administering to a subject in need thereof omadacycline or a pharmaceutically acceptable salt thereof.
PCT/US2021/031608 2020-05-11 2021-05-10 Methods of treating covid-19 using tetracycline compounds WO2021231314A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063022974P 2020-05-11 2020-05-11
US63/022,974 2020-05-11

Publications (2)

Publication Number Publication Date
WO2021231314A1 WO2021231314A1 (en) 2021-11-18
WO2021231314A8 true WO2021231314A8 (en) 2022-09-29

Family

ID=78524913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/031608 WO2021231314A1 (en) 2020-05-11 2021-05-10 Methods of treating covid-19 using tetracycline compounds

Country Status (1)

Country Link
WO (1) WO2021231314A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796215B (en) * 2022-05-27 2023-07-07 贵州医科大学 Application of tirofiban in preparing medicine for treating human respiratory syncytial virus infection
KR20240047717A (en) * 2022-10-05 2024-04-12 한국과학기술원 Anti-viral composition against coronavirus or influenza virus using natural product and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
CA2673466C (en) * 2006-12-21 2016-06-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US9775855B2 (en) * 2011-09-14 2017-10-03 Thomas J. Lewis Compositions comprising macrolide and tetracycline and their uses
WO2016025010A1 (en) * 2014-08-14 2016-02-18 Ugwu Martin A novel broad-spectrum antiviral synergistic pharmaceutical composition for the treatment and prevention of viral infections
WO2017210262A1 (en) * 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections

Also Published As

Publication number Publication date
WO2021231314A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
WO2022047065A3 (en) Compounds and methods for treatment of viral infections
WO2021231314A8 (en) Methods of treating covid-19 using tetracycline compounds
WO2019178005A3 (en) Methods for treating hpv-associated diseases
CR20200553A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
WO2018158306A8 (en) Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
WO2020201833A8 (en) Gepotidacin for use in the treatment of bacterial urinary tract infections
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP4249054A3 (en) Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia
MX2019013815A (en) Hepatitis b virus surface antigen inhibitor.
MY153290A (en) Multivalent avian influenza vaccines
AU2018274028A1 (en) A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
MX2020011367A (en) Oxo-substituted compound.
MX2022005388A (en) Pyrrolidine and piperidine compounds.
IL311227A (en) Therapeutic bacteriophage compositions
WO2022109317A9 (en) Anti-influenza antibodies and combinations thereof
WO2017209588A3 (en) Pharmaceutical formulation comprising cineol and amoxicillin
WO2020132603A3 (en) Salicyl-adenosinemonosulfamate analogs and uses thereof
WO2021081110A3 (en) Peptides and use thereof
CA2489208A1 (en) Interleukin-6 suppressive agent
WO2003032905A3 (en) Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity
WO2011163321A3 (en) Composition and method of treating lipid encapsulated virus infections
WO2021041989A9 (en) Compositions and methods for treatment of influenza a infection
EP1627663A3 (en) Use of a pharmaceutical composition for the treatment of pathologies derived from infection by herpes virus, papillomavirus, hepatitis virus, viral neuralgia, viral dsyplasia, immune-deficiency-induced viral infections and viral neuritis.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21802968

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21802968

Country of ref document: EP

Kind code of ref document: A1